KRAS and pancreatic neoplasm: In order to analyze the time course effect of gemcitabine treatment on VMP1 expression we used PANC-1 and MIAPaCa-2 pancreatic tumor cells harboring a KRAS activating mutation, that are highly resistant to chemotherapy, and BxPC-3 pancreatic tumor cells that do not carry KRAS mutation.